



IDE Vision

80 Caroline Street

Birmingham B3 1UP

United Kingdom

February 5, 2021

IDE Vision Limited acquires the MPSII Macular Pigment Screener from Elektron Eye Technology Limited.

UK based IDE Vision Limited (“IDE”) announced today that on 13 January 2021 it acquired the assets which comprise the business of manufacturing and selling of the MPSII Macular Pigment Screener (MPSII) from Elektron Eye Technology Limited (“EET”).

David Smith, CEO of IDE stated “it is an exciting time for IDE as it enters the ophthalmic market with the MPSII as its core device. Our initial focus will be on the existing customer base for the MPSII who are located across the globe. We will then look to invest in developing the device as part of a system for the professional to use easily and incorporate new modern technology to support it”.

The MPSII was the world’s first commercially viable, patent-protected macular pigment measurement device used to determine the state of the macular pigment which has been associated with the risk of a person developing Age related Macular Degeneration (AMD).

The MPS II measures Macula Pigment Optical Density (MPOD). MPOD directly correlates with the progression of AMD, a blinding condition that afflicts people as they get older. The MPSII allows early intervention and management for optical preservation of the visual field. The most common treatment for a high-risk patient is supplements which contain the carotenoids Lutein and Zeaxanthin.

To understand more about IDE Vision and the MPSII device please contact IDE Vision at;

sales@ide-vision.com

www.ide-vision.com